Insmed Reports Positive 12-Month TPIP PAH Study Data
BRIDGEWATER, N.J., July 16, 2026 Insmed Incorporated has announced positive 12-month results from the ongoing open-label extension (OLE) study...
Phase 1
Advertisement
Diagonal Therapeutics Doses First DIAG723 HHT Patient
WATERTOWN, Mass., July 16, 2026 Diagonal Therapeutics has reached a significant milestone in rare disease drug development by announcing...
Kura Oncology Presents Darlifarnib Plus Cabozantinib Data
SAN DIEGO, July 14, 2026 Kura Oncology announced that updated long-term follow-up data from the ongoing FIT-001 Phase 1a...
Artelo Biosciences Reports Positive ART26.12 Pain Data
SOLANA BEACH, Calif., July 1, 2026 Artelo Biosciences, Inc. announced positive preclinical data demonstrating that its investigational drug candidate...
Revolution Medicines Reports Promising Phase 1/2 Zoldonrasib Combination Data in Metastatic Pancreatic Cancer
REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...
Advertisements
Diakonos Oncology Reports Phase 1 DOC1021 Survival Data
Houston, USA | May 1, 2026 Diakonos Oncology has reported positive Phase 1 clinical data for its investigational DOC1021...
Laguna Gains FDA IND Clearance for LGNA-100 Therapy
SAN FRANCISCO, CALIFORNIA, April 29, 2026 Laguna Biotherapeutics has announced that the U.S. Food and Drug Administration (FDA) has...
Kestrel Therapeutics Doses First Patient in KRAS Trial
WATERTOWN, MASSACHUSETTS, April 28, 2026 Kestrel Therapeutics Inc. has announced a major clinical milestone with the first patient dosed...
Alltrna Launches First Human Trial for tRNA Therapy AP003
CAMBRIDGE, Mass., USA, March 31, 2026 Alltrna has received regulatory approval to initiate the first-in-human clinical trial of AP003,...
Advertisement
